Donor, Graft, and Patient Characteristics
| Patient No. . | Donors . | Grafts . | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | Age/Sex . | CD34 . | CD3 . | Patients . | Engraftment . | ||||||||||||||||
| . | . | pre . | post . | pre . | post . | Age/Sex . | Diagnosis . | ANC . | Patient . | GVHD . | Infections . | ||||||||||
| . | . | . | . | . | . | . | . | 0.5 . | 1 . | 20 . | 50 . | Acute . | Chronic . | CMV . | Bacteria . | Follow-up . | . | ||||
| . | . | . | . | . | . | . | . | . | . | . | . | . | . | D . | P . | Reactivation . | . | Last visit . | Status . | Relapse . | . |
| 1 | 51/M | 6.8 | 4.6 | 363 | 0.45 | 47/M | CML 1CP | 17 | 22 | 11 | 23 | 0 | No | − | + | d +49 | d +674 | Alive | d+302 (Hematol cytog remission after DLI) | ||
| 2 | 24/F | 1.8 | 1.9 | 508 | 0.4 | 22/M | AML 1CR | 14 | 15 | 12 | 20 | 0 | Limited | − | − | No | S viridans | d +645 | Alive | ||
| 3 | 32/M | 7.4 | 7 | 280 | 0.5 | 37/M | AML 1CR | 12 | 13 | 7 | 18 | 0 | No | − | + | d +41 | d +604 | Alive | |||
| 4 | 18/F | 3.6 | 2 | 476 | 0.3 | 21/M | ALL-T 1CR | 12 | 14 | 14 | 36 | 0 | No | + | − | d +45 | d +528 | Dead | d+230. Resistant to chemotherapy | ||
| 5 | 61/M | 4.5 | 4.4 | 165 | 0.3 | 46/M | RAEBt | 13 | 15 | 9 | 19 | 1 | No | + | + | d +44 | d +442 | Alive | |||
| 6 | 35/F | 10 | 4.4 | 644 | 0.3 | 25/F | AML 1CR | 12 | 13 | 10 | 14 | I | No | + | + | d +45/+75 | d +424 | Alive | |||
| 7 | 38/M | 6.6 | 6.6 | 836 | 0.6 | 41/F | CML 1CP | 14 | 27 | 9 | 13 | I | No | − | + | d +44/+105 | L monocyt | d +251 | Dead | of a previous breast cancer | |
| 8 | 42/M | 3.8 | 2.5 | 396 | 0.3 | 38/F | CLL C (IV) | 13 | 15 | 11 | 14 | 0 | No | + | + | No | d +333 | Alive | |||
| 9 | 39/M | — | 1.5 | 438 | 0.5 | 37/F | CMML-AML | 17 | 21 | 13 | 14 | 0 | No | + | + | No | d +312 | Dead | d +120. DLI | ||
| 10 | 32/F | 3.5 | 2.8 | 302 | 0.6 | 37/F | Histiocyt X | 17 | 19 | 23 | 130 | I | No | − | − | No | d +235 | Alive | |||
| 11 | 34/M | 11 | 8.6 | 366 | 0.5 | 37/M | AML 1CR | 11 | 11 | 6 | 12 | 0 | No | NA | − | No | d +228 | Alive | |||
| 12 | 47/M | 3.1 | 2 | 277 | 0.4 | 51/M | RAEBt | 17 | 21 | 23 | 103 | 0 | No | NA | + | d +57 | L monocyt | d +221 | Alive | ||
| 13 | 28/M | 6.8 | 4.7 | 667 | 1 | 32/M | RAEBt | 14 | 17 | 15 | 17 | 0 | No | + | + | d +34 | K pn/P Aer | d +186 | Alive | ||
| 14 | 40/M | 12 | 3.6 | 611 | 2 | 43/F | CML 1CP | 14 | 16 | 8 | 14 | I | No | + | + | d +55 | d +109 | Dead | |||
| 15 | 51/M | 4.9 | 2.4 | 238 | 0.4 | 48/M | CML 1CP | 18 | 19 | 11 | 19 | 0 | No | − | + | d +44 | d +151 | Alive | |||
| 16 | 29/F | 5.7 | 2.9 | 611 | 0.8 | 32/F | CML 1CP | 15 | 16 | 8 | 14 | 0 | No | − | − | No | d +136 | Alive | |||
| 17 | 51/F | 4.9 | 3.17 | 475 | 0.3 | 53/M | ALL 1CR | 10 | 14 | 7 | 20 | 0 | − | − | − | d +36 | d +81 | Alive | |||
| 18 | 52/F | 4.3 | 2.6 | 550 | 0.3 | 54/F | AML 1Rel | 13 | 13 | 7 | 13 | 0 | − | + | − | No | d +74 | Alive | |||
| 19 | 49/M | 5.8 | 1.8 | 446 | 0.5 | 44/M | AML 1Rel | 13 | 15 | 8 | 16 | 0 | − | + | − | No | d +67 | Alive | |||
| 20 | 54/F | 2.4 | 1.46 | 160 | 0.1 | 53/M | ALL 1CR | 12 | 13 | 10 | 16 | I | − | − | − | No | d +60 | Alive | |||
| Median | 40 | 4.9 | 2.9 | 442 | 0.42 | 40 | 14 | 15 | 10 | 17 | |||||||||||
| Patient No. . | Donors . | Grafts . | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | Age/Sex . | CD34 . | CD3 . | Patients . | Engraftment . | ||||||||||||||||
| . | . | pre . | post . | pre . | post . | Age/Sex . | Diagnosis . | ANC . | Patient . | GVHD . | Infections . | ||||||||||
| . | . | . | . | . | . | . | . | 0.5 . | 1 . | 20 . | 50 . | Acute . | Chronic . | CMV . | Bacteria . | Follow-up . | . | ||||
| . | . | . | . | . | . | . | . | . | . | . | . | . | . | D . | P . | Reactivation . | . | Last visit . | Status . | Relapse . | . |
| 1 | 51/M | 6.8 | 4.6 | 363 | 0.45 | 47/M | CML 1CP | 17 | 22 | 11 | 23 | 0 | No | − | + | d +49 | d +674 | Alive | d+302 (Hematol cytog remission after DLI) | ||
| 2 | 24/F | 1.8 | 1.9 | 508 | 0.4 | 22/M | AML 1CR | 14 | 15 | 12 | 20 | 0 | Limited | − | − | No | S viridans | d +645 | Alive | ||
| 3 | 32/M | 7.4 | 7 | 280 | 0.5 | 37/M | AML 1CR | 12 | 13 | 7 | 18 | 0 | No | − | + | d +41 | d +604 | Alive | |||
| 4 | 18/F | 3.6 | 2 | 476 | 0.3 | 21/M | ALL-T 1CR | 12 | 14 | 14 | 36 | 0 | No | + | − | d +45 | d +528 | Dead | d+230. Resistant to chemotherapy | ||
| 5 | 61/M | 4.5 | 4.4 | 165 | 0.3 | 46/M | RAEBt | 13 | 15 | 9 | 19 | 1 | No | + | + | d +44 | d +442 | Alive | |||
| 6 | 35/F | 10 | 4.4 | 644 | 0.3 | 25/F | AML 1CR | 12 | 13 | 10 | 14 | I | No | + | + | d +45/+75 | d +424 | Alive | |||
| 7 | 38/M | 6.6 | 6.6 | 836 | 0.6 | 41/F | CML 1CP | 14 | 27 | 9 | 13 | I | No | − | + | d +44/+105 | L monocyt | d +251 | Dead | of a previous breast cancer | |
| 8 | 42/M | 3.8 | 2.5 | 396 | 0.3 | 38/F | CLL C (IV) | 13 | 15 | 11 | 14 | 0 | No | + | + | No | d +333 | Alive | |||
| 9 | 39/M | — | 1.5 | 438 | 0.5 | 37/F | CMML-AML | 17 | 21 | 13 | 14 | 0 | No | + | + | No | d +312 | Dead | d +120. DLI | ||
| 10 | 32/F | 3.5 | 2.8 | 302 | 0.6 | 37/F | Histiocyt X | 17 | 19 | 23 | 130 | I | No | − | − | No | d +235 | Alive | |||
| 11 | 34/M | 11 | 8.6 | 366 | 0.5 | 37/M | AML 1CR | 11 | 11 | 6 | 12 | 0 | No | NA | − | No | d +228 | Alive | |||
| 12 | 47/M | 3.1 | 2 | 277 | 0.4 | 51/M | RAEBt | 17 | 21 | 23 | 103 | 0 | No | NA | + | d +57 | L monocyt | d +221 | Alive | ||
| 13 | 28/M | 6.8 | 4.7 | 667 | 1 | 32/M | RAEBt | 14 | 17 | 15 | 17 | 0 | No | + | + | d +34 | K pn/P Aer | d +186 | Alive | ||
| 14 | 40/M | 12 | 3.6 | 611 | 2 | 43/F | CML 1CP | 14 | 16 | 8 | 14 | I | No | + | + | d +55 | d +109 | Dead | |||
| 15 | 51/M | 4.9 | 2.4 | 238 | 0.4 | 48/M | CML 1CP | 18 | 19 | 11 | 19 | 0 | No | − | + | d +44 | d +151 | Alive | |||
| 16 | 29/F | 5.7 | 2.9 | 611 | 0.8 | 32/F | CML 1CP | 15 | 16 | 8 | 14 | 0 | No | − | − | No | d +136 | Alive | |||
| 17 | 51/F | 4.9 | 3.17 | 475 | 0.3 | 53/M | ALL 1CR | 10 | 14 | 7 | 20 | 0 | − | − | − | d +36 | d +81 | Alive | |||
| 18 | 52/F | 4.3 | 2.6 | 550 | 0.3 | 54/F | AML 1Rel | 13 | 13 | 7 | 13 | 0 | − | + | − | No | d +74 | Alive | |||
| 19 | 49/M | 5.8 | 1.8 | 446 | 0.5 | 44/M | AML 1Rel | 13 | 15 | 8 | 16 | 0 | − | + | − | No | d +67 | Alive | |||
| 20 | 54/F | 2.4 | 1.46 | 160 | 0.1 | 53/M | ALL 1CR | 12 | 13 | 10 | 16 | I | − | − | − | No | d +60 | Alive | |||
| Median | 40 | 4.9 | 2.9 | 442 | 0.42 | 40 | 14 | 15 | 10 | 17 | |||||||||||
Abbreviations: CML, chronic myeloid leukemia; ALL, acute lymphoblastic leukemia; AML, acute myeloblastic leukemia; CLL, chronic lymphocytic leukemia; CMML, chronic myelomonocytic leukemia; RAEBt, refractory anemia with excess of blasts in transformation; Histiocyt. X, Histiocytosis X; Rel, relapse; GVHD, graft-versus-host disease; DLI, donor lymphocyte infusion; (D) donor and (P) patient seropositive. ANC, absolute neutrophil count and platelets × 10E9/L; NA, not available; values are expressed as 10E6/kg for CD34+/CD3+ cells; K.pn, Klebsiella pneumoniae; P. aer. Pseudomonas aeruginosa.